



Nimbus Therapeutics to Present Updated Preclinical Data From HPK1 Inhibitor Program in Scientific Seminar

CAMBRIDGE, Mass. – Nov. 5, 2020 – [Nimbus Therapeutics](#), a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, will host its second in a series of virtual seminars highlighting the latest data from its HPK1 program. The seminar, titled “Novel, Potent, Selective HPK1 Inhibitors Enhance Immune Activation to Inhibit Tumor Growth,” will take place on Tuesday, Nov. 17, from 11 a.m. to 12 p.m. ET.

Nimbus’ scientific leadership will present new preclinical data on the anti-tumor immune activity of its small-molecule HPK1 inhibitors. These data are featured in [recent poster presentations](#) at the EORTC-NCI-AACR Symposium and the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting.

If you wish to attend the live seminar, please pre-register at: [Nimbus HPK1 Seminar II](#). A replay of the webcast will be available at this link after the event.

A recording of Nimbus’ previous HPK1 seminar can be accessed at <https://bit.ly/NimbusHPK1Seminar>.

About Nimbus Therapeutics

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. The company’s LLC/subsidiary architecture enables diverse and synergistic partnerships to deliver breakthrough medicines. Nimbus is headquartered in Cambridge, Mass. www.nimbustx.com

Media Contact

Lisa Raffensperger, (617) 903-8783
Ten Bridge Communications
lisa@tenbridgecommunications.com